Home » Blog » Oncology Patient Advocacy Spotlight

Oncology Patient Advocacy Spotlight


IP Blog | Dave Melin | October 22, 2014

This week in health care trends, our spotlight on oncology patient advocacy includes updates about more difficult access to medicines, patient advocacy in Washington, and “Movember”.

oncology patient advocacy buttonThe three articles below are from our dedicated Oncology Patient Advocacy e-magazine. We’re constantly adding valuable content to this updateable magazine, so make sure to check our e-magazine frequently for new intelligence. You can follow us on Flipboard or Twitter, or just watch for the links to this and our other magazines in our regular weekly BioBlog emails. (Don’t get our emails yet? Subscribe here!)

Trade Talk Documents Suggest Access to Medicines May Become Harder

After a recent document leak posted by WikiLeaks, some advocacy groups are concerned that new international trade proposals may limit access to medicines for patients in poorer countries. The policy in question currently allows countries to “issue compulsory licenses to a generic drug maker allowing it to copy a patented medicine without the consent of the pharmaceutical company that owns the patent.”

Movember and the Importance of Patient Advocacy

In this funny and insightful post, urologist Dr. Rajiv Singal shares how participating in “Movember” can not only raise money for prostate cancer initiatives, but also provide a starting point for important conversations about screening.

Are brighter days ahead for patient advocates in Washington?

This opinion piece takes a look at legislative health measures over the years, and argues that although there has been a slowing of progress in the past, a spate of recent victories — and the promise of Congress’s still-in-process “21st Century Cures” initiative — indicates that “for patient groups willing to innovate, create and collaborate, opportunity abounds.”


Topics in this Post:



Leave a Comment

Your email address will not be published. Required fields are marked *